What is important for an interventional cardiologist to know about thrombocytes

Česká verzia

Authors: M. Malý ¹ ; I. Marinov ²; M. Oravec ¹; J. Veselka ¹
Authors place of work: Kardiovaskulární centrum, Fakultní nemocnice v Motole, Praha ¹; Ústav hematologie a krevní transfuze, Praha ²
Published in the journal: Kardiol Rev Int Med 2010, 12(3): 134-137

Summary

Thrombocytes are crucial elements in the development of arterial thrombosis as an underlying condition of the acute coronary syndrome. Knowledge of the pathophysiology of adhesion, activation and aggregation of thrombocytes is essential for the interpretation of therapeutic targets for thrombosis prevention and treatment. Functional testing of the efficacy of antiplatelet drugs, though not yet routinely performed, is likely to bring further decline in thrombotic complications in the near future.

Keywords:
thrombocytes – adhesion – aggregation – functional testing – aspirin – clopidogrel – prasugrel

Zdroje

1. Coppinger JA, Cagney G, Toomey S et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096–2104.

2. Haslam RJ, Davidson MM, Desjardins JV. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP. Biochem J 1978; 176: 83–95.

3. Savi P, Pflieger AM, Herbert JM. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis 1996; 7: 249–252.

4. Trumel C, Payrastre B, Plantavid M et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156–4165.

5. Kauffenstein G, Bergmeier W, Eckly A et al. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin – a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett 2001; 505: 281–290.

6. Bultas J, Karetová D. Je protidestičkové léčba indikována v primární prevenci? Kardiol Rev 2007; 9: 242–246.

7. Kottke-Marchant K. Importance of platelets response in acute coronary syndromes. Cleve Clin J Med 2009; 76: S2–S7.

8. Cuisset T, Valgimigli M, Mudra H et al. Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. Eurointervention 2010; 6: 39–45.

9. Magniacapra F, DeBruyne B, Muller O et al. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2010; 3: 35–40.

10. Schwarz UR, Geiger J, Walter U et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets – definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145–1152.

11. Bonello L, Camoin-Jau L, Arques S et al. Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance. J Am Coll Cardiol 2008; 51: 1404–1411.

12. Silber S, Albertsson P, Avilés FF et al. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804–847.

13. Montalescot G, Sideris G, Meuleman C et al. ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48: 931–938.

14. Task Force for Diagnosis and Treatment of Non-ST--Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598–1660.

15. Wiviott SD, Braunwald E, McCabe CH et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.

16. Mehta SR, Granger CB, Boden WE et al. TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360: 2165–2175.

17. Kushner FG, Hand M, Smith SC Jr et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271–2306.

18. Thiele H, Schindler K, Friedenberger J et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008; 118: 49–57.

19. Cannon CP, Harrington RA, James S et al. PLATelet inhibition and patient Outcomes (PLATO) Investigators. Comparison of Ticagrelor With Clopidogrel in Patients With a Planned Invasive Strategy for Acute Coronary Syndromes (PLATO): A Randomised Double-Blind Study. Lancet 2010; 375: 283–293.